SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Continued Development of ESS

NEW YORK, NY / ACCESSWIRE / January 7, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).

The report is available here: AMBS January 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“On December 22, Amarantus announced that ongoing engineering activities for ESS are progressing successfully, and AMBS expects to complete the necessary steps to complete the validation process in January. Upon completing the validation studies, AMBS will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas. AMBS has achieved milestones toward validation for ESS. In November 2015, AMBS completed the aseptic process simulation execution and qualification of the process and personnel used in manufacturing,” stated Ajay Tandon, CEO of SeeThruEquity. “We are maintaining our 12-month price target of $45.34 per share.”

Additional highlights from the note are as follows:

Continued Development of ESS

On December 29, Amarantus announced that they have requested Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) to treat GCMN with Engineered Skin Substitute (ESS). It is estimated that the incidence of GCMN, a rare dermatological condition present at birth, is between 8 and 80 births annually in the United States.

On December 22, Amarantus announced that ongoing engineering activities for ESS are progressing successfully, and Amarantus expects to complete the necessary steps to complete the validation process in January. Upon completing the validation studies, AMBS will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas.

Eltoprazine for Treatment of Parkinson’s Levodopa-induced Dyskinesia

On December 16, Amarantus announced the publication of a new independent peer-reviewed publication describing the mechanisms by which Eltoprazine may act to overcome Parkinson’s disease Levodopa-induced Dyskinesia (PD-LID).

On December 15, Amarantus announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) covering the use of combination 5HT1A and 5HT1B agonists, including Eltoprazine, for the treatment of PD-LID.

Retained WallachBeth Capital to Evaluate Divestiture of Diagnostics

On December 10, Amarantus announced that it retained WallachBeth Capital to evaluate strategic options for its MANF gene therapy program. Under the terms of the agreement, WallachBeth Capital will source business development opportunities for the MANF gene therapy program with gene therapy-focused companies that offer a potential synergistic fit.

Please review important disclosures at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS’ Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson’s disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer’s aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF’s discovery.

AMBS’ Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 435383